



上海源叶生物科技有限公司  
 Shanghai yuanye Bio-Technology Co., Ltd  
 电话: 021-61312973 传真: 021-55068248  
 网址: www.shyuanye.com  
 邮箱: shyysw@sina.com

产品名称: **AKT1-2008**  
 产品别名: **Akt1 and Akt2-IN-1**

生物活性:																											
<b>Description</b>	Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC <sub>50</sub> =3.5 nM) and Akt2 (IC <sub>50</sub> =42 nM), with potent and balanced activity.																										
<b>IC<sub>50</sub> &amp; Target</b>	Akt1                      Akt2																										
	3.5 nM (IC <sub>50</sub> )              42 nM (IC <sub>50</sub> )																										
<b>In Vitro</b>	Consistent with the allosteric mode of inhibition, Akt1 and Akt2-IN-1 (Compound 17) is dependent on the PH-domain for Akt inhibition, is selective for Akt1/2 over Akt3 (IC <sub>50</sub> =1900 nM), and is highly selective over other members of the AGC family of kinases (>50 μM vs PKA, PKC, SGK). Akt1 and Akt2-IN-1 (Compound 17) has moderate activity in an hERG binding assay (IC <sub>50</sub> =5610 nM) and is a substrate for human P-glycoprotein[1].																										
<b>In Vivo</b>	Akt1 and Akt2-IN-1 (Compound 17) is well tolerated in at exposures that provide high levels of Akt1 and 2 inhibition in vivo. Akt1 and Akt2-IN-1 (Compound 17) has also been shown to inhibit the growth of A2780 tumors in vivo when used as monotherapy. Akt1 and Akt2-IN-1 (Compound 17) has potent inhibitory activity against Akt1 and 2 in vivo in a mouse lung and efficacy in a tumor xenograft model. Akt1 and Akt2-IN-1 (Compound 17) shows good pharmacokinetics in rat with a low clearance of 4.6 mL/min/kg and a half-life of 3.8 h. Due to the improved cell potency, physical properties, and rodent pharmacokinetics of Akt1 and Akt2-IN-1 (Compound 17), tolerability and Akt inhibition are assessed in mice. Using an acute dosing schedule (IP dosing of 50 mg/kg at times 0, 3, and 8 h), administration of Akt1 and Akt2-IN-1 (Compound 17) is well tolerated in mice and shows high levels of Akt inhibition in mouse lung[1].																										
<b>Solvent&amp;Solubility</b>	<b><i>In Vitro:</i></b> DMSO : ≥ 35 mg/mL (64.86 mM) * "≥" means soluble, but saturation unknown.																										
	<table border="1"> <thead> <tr> <th rowspan="2">Preparing Stock Solutions</th> <th>Solvent</th> <th>Mass</th> <th rowspan="2">1 mg</th> <th rowspan="2">5 mg</th> <th rowspan="2">10 mg</th> </tr> <tr> <th>Concentration</th> <th></th> </tr> </thead> <tbody> <tr> <td></td> <td>1 mM</td> <td></td> <td>1.8531 mL</td> <td>9.2656 mL</td> <td>18.5312 mL</td> </tr> <tr> <td></td> <td>5 mM</td> <td></td> <td>0.3706 mL</td> <td>1.8531 mL</td> <td>3.7062 mL</td> </tr> <tr> <td></td> <td>10 mM</td> <td></td> <td>0.1853 mL</td> <td>0.9266 mL</td> <td>1.8531 mL</td> </tr> </tbody> </table>	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg	Concentration			1 mM		1.8531 mL	9.2656 mL	18.5312 mL		5 mM		0.3706 mL	1.8531 mL	3.7062 mL		10 mM		0.1853 mL	0.9266 mL	1.8531 mL
	Preparing Stock Solutions		Solvent	Mass				1 mg	5 mg	10 mg																	
		Concentration																									
	1 mM		1.8531 mL	9.2656 mL	18.5312 mL																						
	5 mM		0.3706 mL	1.8531 mL	3.7062 mL																						
	10 mM		0.1853 mL	0.9266 mL	1.8531 mL																						
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。																											
<b>References</b>	[1]. Bilodeau MT, Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3178-82.																										